Literature DB >> 33471954

Characteristic facial features and cortical blindness distinguish the DOCK7-related epileptic encephalopathy.

Edda Haberlandt1,2, Taras Valovka1, Tanja Janjic3, Thomas Müller1, Georgios Blatsios4, Daniela Karall1, Andreas R Janecke1,5.   

Abstract

BACKGROUND: The epileptic encephalopathies display extensive locus and allelic heterogeneity. Biallelic truncating DOCK7 variants were recently reported in five children with early-onset epilepsy, intellectual disability, and cortical blindness, indicating that DOCK7 deficiency causes a specific type of epileptic encephalopathy.
METHODS: We identified 23- and 27-year-old siblings with the clinical pattern reported for DOCK7 deficiency, and conducted genome-wide linkage analysis and WES. The consequences of a DOCK7 variant were analyzed on the transcript and protein level in patients' fibroblasts.
RESULTS: We identified a novel homozygous DOCK7 frameshift variant, an intragenic tandem duplication of 124-kb, previously missed by CGH array, in adult patients. Patients display atrophy in the occipital lobe and pontine hypoplasia with marked pontobulbar sulcus, and focal atrophy of occasional cerebellar folia is a novel finding. Recognizable dysmorphic features include normo-brachycephaly, narrow forehead, low anterior and posterior hairlines, prominent ears, full cheeks, and long eyelashes. Our patients function on the level of 4-year-old children, never showed signs of regression, and seizures are largely controlled with multi-pharmacotherapy. Studies of patients' fibroblasts showed nonsense-mediated RNA decay and lack of DOCK7 protein.
CONCLUSION: DOCK7 deficiency causes a definable clinical entity, a recognizable type of epileptic encephalopathy.
© 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.

Entities:  

Keywords:  zzm321990DOCK7zzm321990; cortical blindness; epileptic encephalopathy; nonsense-mediated RNA decay; recognizable syndrome

Mesh:

Substances:

Year:  2021        PMID: 33471954      PMCID: PMC8104163          DOI: 10.1002/mgg3.1607

Source DB:  PubMed          Journal:  Mol Genet Genomic Med        ISSN: 2324-9269            Impact factor:   2.183


INTRODUCTION

The early infantile epileptic encephalopathies (EIEE) represent a large and genetically heterogeneous group of neurodevelopmental disorders diagnosed during early childhood. Variable degrees of social, cognitive, motor, language, and behavioral impairments are observed. Seizures supposedly contribute to developmental impairment and regression (Scheffer et al., 2017). Whole exome sequencing (WES) or targeted gene panels enable a genetic diagnosis in about 30% of EIEE patients. Genetic diagnoses can lead to more accurate treatment in up to 25% of the epilepsy patients, that is, they are required for precision medicine (Heyne et al., 2019; Moller et al., 2019). However, genes whose mutations are known to cause EIEE are most often associated with overlapping and non‐specific phenotypes, complicating the establishment of etiological diagnoses. Recently, a specific phenotype of EIEE (EIEE23, OMIM 615859) was suggested based on the findings in five children aged 3–10 years, who harbored biallelic truncating mutations in the DOCK7 (dedicator of cytokinesis 7) gene (OMIM 615730), that were supposed but not shown to trigger nonsense‐mediated mRNA decay (NMD) (Bai et al., 2019; Perrault et al., 2014; Turkdogan et al., 2019). DOCK7 encodes a guanine nucleotide exchange factor (GEF) that plays a role in axon formation and neuronal polarization (Watabe‐Uchida et al., 2006). We report an adult sibling‐pair displaying the pattern of EIEE23; these patients function on the level of 4‐year‐old children with largely controlled seizures. We identify a novel homozygous truncating DOCK7 variant, and show that it abrogates protein production.

MATERIALS AND METHODS

Ethical compliance

Written informed consent for molecular genetic studies and publication of data was obtained, and the ethics committee of the Medical University of Innsbruck approved the study. Linkage analysis and WES were performed as reported (Baumann et al., 2017; Waich et al., 2020), and breakpoint sequencing and functional studies are described in Supporting Information.

RESULTS

Clinical characteristics

The two female patients (P1 and P2) are 27 and 23 years old. They were born at term after unremarkable pregnancy and delivery to healthy, consanguineous Austrian parents. Their neonatal course was uneventful, except for the discovery of an atrial septal defect in P2, for which the child was operated on at 5 years of age. Both sisters presented with infantile spasms at 6 months of age, which occurred as many as 50 times a day. Over the next months, both patients showed different types of seizures, including myoclonus, partial complex seizures with rotation of the head, drop attacks, and tonic seizures. Control was initially poor in both sisters despite the administration of multiple antiepileptic drugs in various combinations. Electroencephalography (EEG) performed at 11 months of age in P1 and at 5 months of age in P2 showed a pattern consistent with hypsarrhythmia. Subsequent EEG studies showed multifocal epileptic activity in both sisters. Current antiepileptic therapy consists of levetiracetam, clobazam, zonisamide, and midazolam to terminate prolonged seizures. Lack of reaction to visual stimuli was evident during the first months of life; a fine horizontal and vertical nystagmus in both eyes and lack of object fixation first suggested Leber congenital amaurosis (LCA) in both patients. However, pupillary reactions and fundoscopy were normal in both sisters, and the scotopic flash evoked visual potentials (FEVP) showed a normal waveform of markedly decreased amplitude in both patients, which led to a diagnosis of cortical blindness. A photopic Ganzfeld electroretinogram (GF‐ERG) showed mildly reduced amplitudes in P1 at 20 years of age, indicating some degree of retinal dysfunction; scotopic testing was not possible due to lack of cooperation. Currently, both individuals still display grossly abnormal visual pursuit, but can ambulate with moderate speed in known environment. P1 correctly identifies large objects and colors, and P2 has nearly no vision. Patients’ adult body height and occipitofrontal head circumference measures are 163, 164, 56 and 54 cm, respectively, and they are mildly obese. Patients show recognizable facial features (Figure 1, P1 and P2). Both patients entered and completed puberty at appropriate age.
FIGURE 1

Typical dysmorphic facial features and typical brain MRI abnormalities in EIEE23. Photographs of P1 and P2 at 19 and 15 years of age. Normo‐brachycephaly, narrow forehead, low anterior and posterior hairlines, protruding and low‐set ears, wide and anteverted nasal tip, full cheeks and periorbital fullness, long eyelashes, smooth and short philtrum and thin upper lip, and highly arched palate are present in P1 and P2, as in three reported patients (A1, A2, and B1, reprinted with permission). Pontine hypoplasia of different degree (arrow heads) with abnormally marked pontobulbar sulci (arrows) in P1 at age 20 years (a) and P2 at age 16 years (b) as compared to age‐matched control (c) (T1, sagittal sections). (d) Cortical and subcortical atrophy of occipital gyri in P2 at age 16 years as compared to age‐matched control (e), and (f) focal atrophy of cerebellar folia in P2, and (g) age‐matched control (T2, transverse section)

Typical dysmorphic facial features and typical brain MRI abnormalities in EIEE23. Photographs of P1 and P2 at 19 and 15 years of age. Normo‐brachycephaly, narrow forehead, low anterior and posterior hairlines, protruding and low‐set ears, wide and anteverted nasal tip, full cheeks and periorbital fullness, long eyelashes, smooth and short philtrum and thin upper lip, and highly arched palate are present in P1 and P2, as in three reported patients (A1, A2, and B1, reprinted with permission). Pontine hypoplasia of different degree (arrow heads) with abnormally marked pontobulbar sulci (arrows) in P1 at age 20 years (a) and P2 at age 16 years (b) as compared to age‐matched control (c) (T1, sagittal sections). (d) Cortical and subcortical atrophy of occipital gyri in P2 at age 16 years as compared to age‐matched control (e), and (f) focal atrophy of cerebellar folia in P2, and (g) age‐matched control (T2, transverse section) P1 and P2 started to walk at 20 months of age, and today patients require assistance to ambulate in unknown environment. Both patients can eat by themselves, can brush their teeth unaided, and are continent by day since age 12 years. Both patients rarely point or use their hands to communicate, but can use objects and perform easy tasks in a sheltered workshop; P1 can assemble a 48‐piece puzzle, and P2 can cut vegetables in the community kitchen. Both patients speak grammatically correct sentences, referring to simple subjects, and understand simple commands, and can designate body parts on demand. They can smile in and out of social context. They display nearly no visual contact. Overall, their skills were rated as on the level of 4‐year‐old children by using the SON‐R 2½‐7 non‐verbal intelligence test, and by non‐formal clinical assessment, and they never showed signs of regression. Neurological examination was otherwise unremarkable. A metabolic work‐up, including plasma triglycerides, cholesterol, amino acid concentrations, and urine organic acid chromatography, was normal in both sisters. All previously reported structural brain abnormalities were present in both siblings, but the focal atrophy of cerebellar folia is a novel finding (Figure 1a–g). Major clinical findings of our and of reported patients are compiled in Table 1.
TABLE 1

DOCK7 variants in patients with a recognizable type of epileptic encephalopathy

ReferenceThis studyBai et al. (2019)Perrault et al. (2014)Turkdogan et al. (2019)
Patient IDP1P2CPatient A‐1Patient A‐2Patient B‐1D
Age (years)2723375103
SexFemaleFemaleFemaleFemaleFemaleFemaleMale
EthnicityAustrianAustrianChineseFrench‐CanadianFrench‐CanadianFrenchTurkish
Parental consanguinityYesYesNoNoNoNoYes
DOCK7 variants a HomozygousHomozygousCompound‐het.Compound‐het.Compound‐het.Compound‐het.Homozygous
Variant typeIntragenic 124 kb tandem duplicationIntragenic 124 kb tandem duplicationSplice/stopStop/frameshiftStop/frameshiftStop/stopStop
cDNA variant b c.390_3936dupc.390_3936dupc.5929‐1G>C/c.2479C>Tc.3709C>T/c.2510delAc.3709C>T/c.2510delAc.983C>G/c.6232G>Tc.3350T>A
Protein variantLoss of protein c Loss of protein c p.?/p.Arg827 a p.Arg1237 a /p.Asp837Alafs a 48p.Arg1237 a /p.Asp837Alafs a 48p.Ser328 a /p.Glu2078 a p.Leu1117 a
hg19 positionNC_000001.10:g.62993145_63116725dupNC_000001.10:g.62993145_63116725dupNC_000001.10:g.62941023C>G /NC_000001.10:g.62995020G>A/NC_000001.10:g.63021582delTNC_000001.10:g.62995020G>A/NC_000001.10:g.63021582delTNC_000001.10:g.63100496G>C/NC_000001.10:g.62923324NC_000001.10:g.63003683A>T
Age of onset and initial frequency of seizures6 months 100 times/day6 months 100 times/day6 months 20 times/dayBetween 2 and 4 monthsBetween 2 and 4 months 50 times/day6 months3.5 months
Types of observed seizuresBNS, myoclonus, partial complex seizures with rotation of the head, drop attacks, and tonic seizuresBNS, myoclonus, partial complex seizures with rotation of the head, drop attacks, and tonic seizuresInfantile spasmTonic seizures infantile spasms seizures, despite antiepileptic therapyTonic seizures myoclonus partial complex seizures with rotation of the head, drop attacks, and tonic seizures seizures, despite antiepileptic therapyEye revulsion, rhythmic arm and body movements. Short absencesStatus epilepticus frequent focal motor seizures
Currently, seizure‐free under antiepileptic therapyCurrently, short absences despite antiepileptic therapyIneffective ketogenic dietIneffective ketogenic dietWhen last seen, repeated tonic‐clonic seizures, despite antiepileptic therapySeizure‐free from 13 months with clobazam
EEG, initial and on follow‐upHypsarrhythmia, multifocal epileptic activityHypsarrhythmia, multifocal epileptic activityHypsarrhythmia, multifocal epileptic activityHypsarrhythmia, multifocal epileptic activityMultifocal epileptic activityMultifocal epileptic activity with occasional electroclinical spasmsInitial EEG examinations showed generalized sharp waves
cMRI(at age 20 years) Abnormally marked pontobulbar sulcus, mild pontine hypoplasia, atrophy in occipital white and gray matter(at age 16 years) Abnormally marked pontobulbar sulcus, mild pontine hypoplasia, atrophy in occipital white and gray matter. Focal atrophy of occasional cerebellar folia(at age 3 years) Abnormally marked pontobulbar sulcus, mild pontine hypoplasia, thin corpus callosum, dilation of lateral ventricles, pachygyria(at age 25 months) Abnormally marked pontobulbar sulcus, mild pontine hypoplasia, a thin and short corpus callosum, and abnormal signals (T2 hyperintensities) with atrophy in the occipital white and gray matter(at age 8 months) Mild hypoplasia of the corpus callosum(at age 2 years) Abnormally marked pontobulbar sulcus, mild pontine hypoplasia, and abnormal signals (T2 hyperintensities) with atrophy in the occipital white and gray matter(at age 33 months) Marked pontobulbar sulcus, pontine hypoplasia, and thin corpus callosum. Increased signal and atrophy in the white and gray matter of the occipital lobe. Absence of interventricular septum. Mild interdigitation of gyri across the interhemispheric fissure
Facial featuresLow anterior and posterior hairline, highly arched palate, some periorbital fullness, telecanthus, long eyelashes, a broad nasal tip. Low‐set and protruding ears. Smooth and short philtrum and thin upper lipLow anterior and posterior hairline, highly arched palate, periorbital fullness, telecanthus, long eyelashes, a broad nasal tip with anteverted nares. Low‐set and protruding earsLow posterior hairlines, highly arched palate, gingival maldevelopment, telecanthus, long eyelashes, low‐set, abnormally shaped and protruding ears, periorbital fullness, broad nasal tip, large nasal rootLow anterior hairline, some periorbital fullness, telecanthus, long eyelashes, a broad nasal tip with anteverted naresLow anterior hairline, some periorbital fullness, telecanthus, long eyelashes, a broad nasal tip with anteverted naresBitemporal narrowness, a low anterior hairline, thick eyebrows, synophrys, telecanthus, long eyelashes, enophthalmia, large and prominent nasal root, a bulbous nasal tip, a thick helix and earlobes, a short philtrum, full lips and everted lower lip, spaced incisorsDysmorphic features include normo‐brachycephaly, narrow forehead, low anterior hairline, wide and anteverted nasal tip, prominent ears, full cheeks, long eyelashes, smooth and short philtrum and thin upper lip
Eye abnormalityLack of reaction to visual stimuli during the first months of life; a fine horizontal and vertical nystagmus in both eyes, and lack of object fixation. Normal pupillary reactions and fundoscopy. FEVP: normal waveform of markedly decreased amplitude, cortical blindness. Photopic GF‐ERG: mildly reduced amplitudes. Identifies large objects and colorsLack of reaction to visual stimuli during the first months of life; a fine horizontal and vertical nystagmus in both eyes, and lack of object fixation. Normal pupillary reactions and fundoscopy. FEVP: normal waveform of markedly decreased amplitude, cortical blindness. Nearly no visionLack of ocular reaction to visual stimulus, binoculus optometric obstacles, horizontal optokinetic nystagmus, left strabismus. Flash evoked visual potentials (FEVP) show abnormal waveform including a longer latency in right eye and decreased amplitude in both eyes cortical blindnessNormal eye movements, pupillary reaction, and fundus. Lack of ocular reaction to visual stimulus, binoculus optometric obstacles, cortical blindness. Currently, grossly normal visual pursuit, although with difficulty following objects in the upper visual fieldsNormal eye movements, pupillary reaction, and fundus. Lack of ocular reaction to visual stimulus, binoculus optometric obstacles, cortical blindness. Can follow a moving object, but does not see well enough to play with toysLack of ocular reaction to visual stimulus, cortical blindness. Evoked visual potentials were unremarkable, but electroretinographic (ERG) traces were ambiguous. Ophthalmological examinations repeated at 2 and 9 years of age showed unchanged retinal aspect and normal ERG traces, leading to the diagnosis of cortical blindness. Currently, there are wandering eye movements and a complete absence of reaction to visual threat and light stimulationNormal ophthalmologic examination except for prolonged latencies of FVEP, cortical blindness
HeartNormalAtrial septal defectAtrial septal defectAortic supravalvular stenosis, bicuspid valveNormal
LanguageUnderstands and speaks grammatically correct sentences of a few words, make use of cell phones, follow simple commands, can designate body parts on demandUnderstands and speaks grammatically correct sentences of a few words, make use of cell phones, follow simple commands, can designate body parts on demandLack of speechLack of speech, understands a few simple commandsSpeaks 30 words and associates two words. She can designate body parts on demand and understand simple commandsRepeating three words, understands simple commandsLack of speech, follows some simple verbal commands
Psychomotor developmentStarted to walk at 20 months of age. Today, requires assistance to ambulate in unknown environment. Can eat by herself, can brush her teeth unaided, and is continent by day since age 12 years. Rarely point or uses her hands to communicate, but can use objects and perform easy tasks in a sheltered workshop; can assemble a 48‐piece puzzle. Displays nearly no visual contactStarted to walk at 20 months of age. Today, requires assistance to ambulate in unknown environment. Can eat by herself, can brush her teeth unaided, and is continent by day since age 12 years. Rarely point or uses her hands to communicate, but can use objects and perform easy tasks in a sheltered workshop; Displays nearly no visual contactWalking unstably at 28 months, sits, crawls and stands by herselfWalking at 20 months, with help. Cannot eat by herself, does not point or use her hands to communicateWalking at 28 months, can run, cannot jump. Eats with a spoon and has a pincer grasp but cannot point to objectsModerate hypotonia, walking at 22 months, can walk without help in known environments. Can grasp objects, but not point or communicate with hands. Brings a spoon to her mouth, but cannot eat by herselfAt 35 months delayed gross and fine motor functions ‐ about at the developmental level of 15 and 8 months, respectively, lack of any visual contact with faces or objects.

None of these variants is listed in gnomAD.

Coding sequence nomenclature refers to NCBI reference NM_001271999.1/Ensembl reference ENST00000454575.6.

Loss of protein as determined in patients’ fibroblasts; FEVP, Scotopic flash evoked visual potentials; GF‐ERG, Ganzfeld electroretinogram.

DOCK7 variants in patients with a recognizable type of epileptic encephalopathy None of these variants is listed in gnomAD. Coding sequence nomenclature refers to NCBI reference NM_001271999.1/Ensembl reference ENST00000454575.6. Loss of protein as determined in patients’ fibroblasts; FEVP, Scotopic flash evoked visual potentials; GF‐ERG, Ganzfeld electroretinogram.

Genetic and protein studies

Linkage analysis with all individuals in generations III‐V excluded 97% of the genome to harbor the disease locus (Figure 2a,b). WES analysis in P1 identified homozygosity for an intragenic 124‐kb tandem duplication in DOCK7 (NC_000001.11:g.62527474_62651054dup, NM_001271999.1:c.390_3936dup), comprising exons 5–31, as determined by genomic breakpoint and by fibroblast cDNA sequencing (Figure 2c,d). The duplication causes a frameshift and DOCK7 deficiency (Figure 2e) via NMD, as demonstrated by partial mRNA rescue with NMD inhibitor puromycin prior to fibroblast culture harvesting. To detect residual DOCK7 protein in whole‐cell lysates, a polyclonal antibody raised in Rabbit with a synthetic peptide corresponding to a region within amino acids 175–225 of human DOCK7 was used.
FIGURE 2

Identification of a novel truncating DOCK7 variant in EIEE23. (a) Family under study and (b) homozygosity mapping results. (c) Duplex PCR amplifies part of DOCK7 intron 31 and an abnormal intron 31‐intron 4 junction fragment in heterozygotes and homozygotes for a large intragenic tandem duplication in DOCK7 (d); previously identified DOCK7 variants are indicated. (e) DOCK7 protein is lacking in patients’ fibroblasts

Identification of a novel truncating DOCK7 variant in EIEE23. (a) Family under study and (b) homozygosity mapping results. (c) Duplex PCR amplifies part of DOCK7 intron 31 and an abnormal intron 31‐intron 4 junction fragment in heterozygotes and homozygotes for a large intragenic tandem duplication in DOCK7 (d); previously identified DOCK7 variants are indicated. (e) DOCK7 protein is lacking in patients’ fibroblasts This duplication also contains the complete ANGPTL3 gene, which resides within exon 14 of DOCK7 and is transcribed from the other strand. ANGPTL3 deficiency was associated with a form of hypobetalipoproteinemia (Musunuru et al., 2010); our patients apparently have four intact copies of ANGPTL3 and repeatedly normal serum lipid levels. Conventional karyotyping after GTG‐banding at a 500 band resolution showed normal female karyotypes, 46,XX. Chromosomal microarray analysis (Illumina HumanCytoSNP‐12v2 BeadChip SNP array with 300 k markers) in P1 had missed the homozygous DOCK7 duplication due to a sparsity of markers in the region.

DISCUSSION

We report here, to the best of our knowledge, for the first time the outcome of DOCK7 deficiency in two adult patients and corroborate the hypothesis that there is a distinctive EIEE23 phenotype that consists of an infantile‐onset epilepsy, severe neurodevelopmental delay, cortical blindness, and the typical facial features and common brain abnormalities described above. Additional developmental brain abnormalities were present in single patients each, such as focal atrophy of cerebellar folia in P2, the interdigitation of gyri across the interhemispheric fissure and the absence of the interventricular septum (Turkdogan et al., 2019), and pachygyria and dilation of lateral ventricles (Bai et al., 2019). In six of seven patients reported to date, epilepsy was largely controlled by multi‐pharmacotherapy, onward from the ages of 16 months to 6 years. Importantly, our two patients continuously acquired skills, in particular attention span and social communication skills over the years, and participate in daily life at home and outside. This outcome appears encouraging with respect to the five children previously described with biallelic truncating DOCK7 mutations, at ages 3–10 years, and who all showed severe psychomotor retardation; there was no speech development in three of five patients, 30 words at age 5 years in one patient and repeating the last three words of sentences at age 10 years in another patient. Only one patient was able to eat with a spoon at age 7 years. CNV calling in WES data identified a frameshifting triplication of exons 5–31 of the DOCK7 gene in the proband. To the best of our knowledge, we are the first to demonstrate NMD and DOCK7 deficiency in patients’ fibroblasts as the consequence of a truncating DOCK7 variant, although biallelic truncating mutations were identified in all five previously reported patients (Bai et al., 2019; Perrault et al., 2014; Turkdogan et al., 2019). DOCK7 plays a key role in neurogenesis by promoting the differentiation and transition of radial glial cells to basal progenitors and neurons (Yang et al., 2012). DOCK7 also regulates tangential neuroblast migration in the postnatal mouse forebrain given that knockdown of DOCK7 alone is sufficient to cause defects in neurogenesis (Nakamuta et al., 2017). DOCK7 is expressed in GABAergic interneurons in the central nervous system. The reduced ERG amplitudes in our patient might indicate the involvement of GABAergic retinal amacrine cells as well as DOCK7 expression in the retina, which would need to be addressed with further studies. It is of interest that a strong conserved craniofacial‐specific enhancer (identifier: GH01J062686) localizes within and around exon 1 of DOCK7 (Wilderman et al., 2018). It remains highly speculative to suggest that premature stop codons in the downstream coding sequence alter the pattern of transcription factor binding to this craniofacial‐specific enhancer and thereby lead to the recognizable syndromic features of patients with DOCK7 deficiency. Altogether, our observation validates the hypothesis that loss of DOCK7 function causes a recognizable form of EIEE, with the hallmarks of cortical blindness and common developmental brain abnormalities, and might potentially be clinically diagnosed based on the shared facial features.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS

EH and ARJ participated in the conception of the study. ARJ drafted the manuscript. All authors collected and analyzed data, interpreted the results, and revised the manuscript. All authors read and approved the final manuscript. Supplementary Material Click here for additional data file.
  13 in total

1.  A novel truncating mutation of DOCK7 gene with an early-onset non-encephalopathic epilepsy.

Authors:  Dilsad Turkdogan; Ayberk Turkyilmaz; Zeliha Gormez; Gunes Sager; Gazanfer Ekinci
Journal:  Seizure       Date:  2019-01-16       Impact factor: 3.184

2.  ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.

Authors:  Ingrid E Scheffer; Samuel Berkovic; Giuseppe Capovilla; Mary B Connolly; Jacqueline French; Laura Guilhoto; Edouard Hirsch; Satish Jain; Gary W Mathern; Solomon L Moshé; Douglas R Nordli; Emilio Perucca; Torbjörn Tomson; Samuel Wiebe; Yue-Hua Zhang; Sameer M Zuberi
Journal:  Epilepsia       Date:  2017-03-08       Impact factor: 5.864

3.  Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia.

Authors:  Kiran Musunuru; James P Pirruccello; Ron Do; Gina M Peloso; Candace Guiducci; Carrie Sougnez; Kiran V Garimella; Sheila Fisher; Justin Abreu; Andrew J Barry; Tim Fennell; Eric Banks; Lauren Ambrogio; Kristian Cibulskis; Andrew Kernytsky; Elena Gonzalez; Nicholas Rudzicz; James C Engert; Mark A DePristo; Mark J Daly; Jonathan C Cohen; Helen H Hobbs; David Altshuler; Gustav Schonfeld; Stacey B Gabriel; Pin Yue; Sekar Kathiresan
Journal:  N Engl J Med       Date:  2010-10-13       Impact factor: 91.245

4.  Mutations in DOCK7 in individuals with epileptic encephalopathy and cortical blindness.

Authors:  Isabelle Perrault; Fadi F Hamdan; Marlène Rio; José-Mario Capo-Chichi; Nathalie Boddaert; Jean-Claude Décarie; Bruno Maranda; Rima Nabbout; Michel Sylvain; Anne Lortie; Philippe P Roux; Elsa Rossignol; Xavier Gérard; Giulia Barcia; Patrick Berquin; Arnold Munnich; Guy A Rouleau; Josseline Kaplan; Jean-Michel Rozet; Jacques L Michaud
Journal:  Am J Hum Genet       Date:  2014-05-08       Impact factor: 11.025

Review 5.  From next-generation sequencing to targeted treatment of non-acquired epilepsies.

Authors:  Rikke S Møller; Trine B Hammer; Guido Rubboli; Johannes R Lemke; Katrine M Johannesen
Journal:  Expert Rev Mol Diagn       Date:  2019-02-04       Impact factor: 5.225

6.  Dual role for DOCK7 in tangential migration of interneuron precursors in the postnatal forebrain.

Authors:  Shinichi Nakamuta; Yu-Ting Yang; Chia-Lin Wang; Nicholas B Gallo; Jia-Ray Yu; Yilin Tai; Linda Van Aelst
Journal:  J Cell Biol       Date:  2017-10-31       Impact factor: 10.539

7.  Novel DOCK7 mutations in a Chinese patient with early infantile epileptic encephalopathy 23.

Authors:  Bing Bai; Yi-Ran Guo; Yin-Hong Zhang; Chan-Chan Jin; Jin-Man Zhang; Hong Chen; Bao-Sheng Zhu
Journal:  Chin Med J (Engl)       Date:  2019-03-05       Impact factor: 2.628

8.  Targeted gene sequencing in 6994 individuals with neurodevelopmental disorder with epilepsy.

Authors:  Henrike O Heyne; Mykyta Artomov; Florian Battke; Claudia Bianchini; Douglas R Smith; Nora Liebmann; Vasisht Tadigotla; Christine M Stanley; Dennis Lal; Heidi Rehm; Holger Lerche; Mark J Daly; Ingo Helbig; Saskia Biskup; Yvonne G Weber; Johannes R Lemke
Journal:  Genet Med       Date:  2019-05-06       Impact factor: 8.822

9.  DOCK7 interacts with TACC3 to regulate interkinetic nuclear migration and cortical neurogenesis.

Authors:  Yu-Ting Yang; Chia-Lin Wang; Linda Van Aelst
Journal:  Nat Neurosci       Date:  2012-07-29       Impact factor: 24.884

10.  High-Resolution Epigenomic Atlas of Human Embryonic Craniofacial Development.

Authors:  Andrea Wilderman; Jennifer VanOudenhove; Jeffrey Kron; James P Noonan; Justin Cotney
Journal:  Cell Rep       Date:  2018-05-01       Impact factor: 9.423

View more
  1 in total

1.  Homozygosity for a Novel DOCK7 Variant Due to Segmental Uniparental Isodisomy of Chromosome 1 Associated with Early Infantile Epileptic Encephalopathy (EIEE) and Cortical Visual Impairment.

Authors:  Fatma Kivrak Pfiffner; Samuel Koller; Anika Ménétrey; Urs Graf; Luzy Bähr; Alessandro Maspoli; Annette Hackenberg; Raimund Kottke; Christina Gerth-Kahlert; Wolfgang Berger
Journal:  Int J Mol Sci       Date:  2022-07-02       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.